| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Center for Immunology and Microbial Disease Research, Albany Medical College, Albany, NY 12208;
Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106; and
Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595
IgA is considered to be the principal Ab involved in defense against pathogens in the mucosal compartment. Using mice with a targeted disruption in IgA gene expression (IgA-/- mice), we have examined the precise role of IgA in protective anti-influenza responses after intranasal vaccination. IgA-/- mice immunized intranasally with soluble hemagglutinin (hemagglutinin subtype 1) and neuraminidase (neuraminidase subtype 1) vaccine in the absence of adjuvant were found to be more susceptible to influenza virus infection than IgA+/+ mice (13 vs 75% survival after virus challenge). Inclusion of IL-12 during immunization restored the protective efficacy of the vaccine to that seen in IgA+/+ animals. IgA-/- mice had no detectable IgA expression, but displayed enhanced serum and pulmonary IgM and IgG Ab levels after IL-12 treatment. Assessment of T cell function revealed markedly depressed splenic lymphoproliferative responses to PHA in IgA-/- animals compared with IgA+/+ mice. Furthermore, IgA-/- animals displayed impaired T cell priming to the H1N1 subunit vaccine, with concomitant reduction in recall memory responses due to a defect in APC function. Collectively, these results provide evidence that a major role of IgA is to facilitate presentation of Ag to mucosal T cells. IL-12 treatment can overcome IgA deficiency by providing adequate T cell priming during vaccination.
This article has been cited by other articles:
|
|
 |
|
  F. Zhou, A. Goodsell, Y. Uematsu, and M. Vajdy Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant Clin. Vaccine Immunol., April 1, 2009; 16(4): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Ray, Y. Cong, A. K. Murthy, D. M. Selby, K. E. Klose, J. R. Barker, M. N. Guentzel, and B. P. Arulanandam Oral Live Vaccine Strain-Induced Protective Immunity against Pulmonary Francisella tularensis Challenge Is Mediated by CD4+ T Cells and Antibodies, Including Immunoglobulin A Clin. Vaccine Immunol., April 1, 2009; 16(4): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rangel-Moreno, D. M. Carragher, R. S. Misra, K. Kusser, L. Hartson, A. Moquin, F. E. Lund, and T. D. Randall B Cells Promote Resistance to Heterosubtypic Strains of Influenza via Multiple Mechanisms J. Immunol., January 1, 2008; 180(1): 454 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Baron, R. Singh, and D. W. Metzger Inactivated Francisella tularensis Live Vaccine Strain Protects against Respiratory Tularemia by Intranasal Vaccination in an Immunoglobulin A-Dependent Fashion Infect. Immun., May 1, 2007; 75(5): 2152 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Arnaboldi, M. J. Behr, and D. W. Metzger Mucosal B Cell Deficiency in IgA-/- Mice Abrogates the Development of Allergic Lung Inflammation J. Immunol., July 15, 2005; 175(2): 1276 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pammit, V. N. Budhavarapu, E. K. Raulie, K. E. Klose, J. M. Teale, and B. P. Arulanandam Intranasal Interleukin-12 Treatment Promotes Antimicrobial Clearance and Survival in Pulmonary Francisella tularensis subsp. novicida Infection Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4513 - 4519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sun, F.-E. Johansen, L. Eckmann, and D. W. Metzger An Important Role for Polymeric Ig Receptor-Mediated Transport of IgA in Protection against Streptococcus pneumoniae Nasopharyngeal Carriage J. Immunol., October 1, 2004; 173(7): 4576 - 4581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Lawrence and B. A. Vorderstrasse Activation of the Aryl Hydrocarbon Receptor Diminishes the Memory Response to Homotypic Influenza Virus Infection but Does Not Impair Host Resistance Toxicol. Sci., June 1, 2004; 79(2): 304 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lim and K. S.J. Elenitoba-Johnson The Molecular Pathology of Primary Immunodeficiencies J. Mol. Diagn., May 1, 2004; 6(2): 59 - 83. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lynch, D. E. Briles, and D. W. Metzger Increased Protection against Pneumococcal Disease by Mucosal Administration of Conjugate Vaccine plus Interleukin-12 Infect. Immun., August 1, 2003; 71(8): 4780 - 4788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Albu, A. Jones-Trower, A. M. Woron, K. Stellrecht, C. C. Broder, and D. W. Metzger Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins J. Virol., May 15, 2003; 77(10): 5589 - 5597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. McNeal, J. L. VanCott, A. H. C. Choi, M. Basu, J. A. Flint, S. C. Stone, J. D. Clements, and R. L. Ward CD4 T Cells Are the Only Lymphocytes Needed To Protect Mice against Rotavirus Shedding after Intranasal Immunization with a Chimeric VP6 Protein and the Adjuvant LT(R192G) J. Virol., January 15, 2002; 76(2): 560 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Silvey, A. B. Hutchings, M. Vajdy, M. M. Petzke, and M. R. Neutra Role of Immunoglobulin A in Protection against Reovirus Entry into Murine Peyer's Patches J. Virol., November 15, 2001; 75(22): 10870 - 10879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Arulanandam, J. M. Lynch, D. E. Briles, S. Hollingshead, and D. W. Metzger Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity against Streptococcus pneumoniae Infection Infect. Immun., November 1, 2001; 69(11): 6718 - 6724. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
